18F-MK-6240 for Alzheimer's Disease

"According to clinicaltrials.gov, this study has paused its recruitment process as of October 7th 2022; however, there are currently 553 other trials actively seeking participants. Initially posted on March 22nd 2019, the trial is not presently in need of additional volunteers."

"As of now, 7 clinical trials for 18F-MK-6240 are underway with none in their third phase. The bulk of these studies take place in Philadelphia, Pennsylvania yet 9 other sites across the country have also joined this medical research effort."

"At the moment, this research is not recruiting any further participants. The trial was initially posted on March 22nd 2019 and recently updated on October 7th 2022. Should you be looking for other studies to join, there are 546 trials in search of individuals with Alzheimer's disease while another 7 require enrollees for 18F-MK-6240 treatments."

"Since 2010, 18F-MK-6240 has been explored through clinical trials. The initial attempt was carried out in 2010 and sponsored by Bayer. This trial included 161 participants and resulted in the drug being granted N/A approval. Presently, there are 7 active studies taking place across 3 cities and 2 countries involving this compound."

"The requirements to join this investigation are a diagnosis of Alzheimer's disease and being within the age range between 35-85. Approximately 150 individuals will be included in the trial."

"To qualify for this trial, individuals must be between 35 and 85 years of age. Those younger than 18 have 23 trials available to them, while those over 65 can choose from 543 options."

"Due to the lack of data supporting 18F-MK-6240's efficacy and safety, our team at Power has assigned it an estimated rating of 1."